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Abstract
Background: Sciatica has a substantial impact on patients, and is associated with high healthcare and societal
costs. Although there is variation in the clinical management of sciatica, the current model of care usually involves
an initial period of ‘wait and see’ for most patients, with simple measures of advice and analgesia, followed by
conservative and/or more invasive interventions if symptoms fail to resolve. A model of care is needed that does
not over-treat those with a good prognosis yet identifies patients who do need more intensive treatment to help
with symptoms, and return to everyday function including work. The aim of the SCOPiC trial (SCiatica Outcomes in
Primary Care) is to establish whether stratified care based on subgrouping using a combination of prognostic and
clinical information, with matched care pathways, is more effective than non-stratified care, for improving time to
symptom resolution in patients consulting with sciatica in primary care. We will also assess the impact of stratified
care on service delivery and evaluate its cost-effectiveness compared to non-stratified care.
Methods/Design: Multicentre, pragmatic, parallel arm randomised trial, with internal pilot, cost-effectiveness
analysis and embedded qualitative study. We will recruit 470 adult patients with sciatica from general practices in
England and Wales, over 24 months. Patients will be randomised to stratified care or non-stratified care, and treated
in physiotherapy and spinal specialist services, in participating NHS services. The primary outcome is time to first
resolution of sciatica symptoms, measured on a 6-point ordered categorical scale, collected using text messaging.
Secondary outcomes include physical function, pain intensity, quality of life, work loss, healthcare use and
satisfaction with treatment, and will be collected using postal questionnaires at 4 and 12-month follow-up.
Semi-structured qualitative interviews with a subsample of participants and clinicians will explore the acceptability
of stratified care.
Discussion: This paper presents the details of the rationale, design and processes of the SCOPiC trial. Results from
this trial will contribute to the evidence base for management of patients with sciatica consulting in primary care.
Trial registration: ISRCTN75449581, date: 20.11.2014.
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Background
About 60% of patients with low back pain (LBP) report
pain in the leg (s) [1] although not all will be diagnosed
as having sciatica. Sciatica is a common variation of LBP
presenting with radiating pain in the leg and often
accompanied by variable neurological changes in sensa-
tion, reflex or muscle strength in the leg [2]. The most
common reason for sciatica symptoms is a disc prolapse
compressing or irritating a spinal nerve root [2]. Sciatica
prevalence estimates vary widely from 1.2 to 43%, a vari-
ation that is related to using different diagnostic criteria
and sampling methods [3]. It is believed that many
patients with sciatica have a favourable outcome and
experience resolution of symptoms within 12 weeks
from onset [2, 4]. However, a substantial proportion
(estimated at up to 30%) continues to suffer with pain
for a year or more [2]. Studies from primary and second-
ary care show that recovery after one year is moderate,
varying from 49 to 58%, depending on the definition of
recovery [5, 6]. The literature indicates that compared to
LBP alone, sciatica has a more substantial impact on
patients, with longer pain episodes [7], it is also respon-
sible for a large proportion of the indirect costs and days
lost from work associated with LBP. A Dutch study
estimated that the cost of sciatica to society represents
13% of all LBP related costs [8], which translates to an
annual impact to the UK economy of £268 million in
direct medical costs and £1.9 billion in indirect costs.
The evidence for treatments for sciatica has been sum-
marised in several systematic reviews [9–12]. Overall they
highlight the poor quality of the research to date, mostly
small trials limited to short-term follow-up. The results of
the reviews indicate that the efficacy and tolerability of
drugs commonly prescribed in primary care for sciatica
(such as non-steroidal anti-inflammatory drugs, cortico-
steroids, antidepressants, anticonvulsants, muscle relax-
ants and opioid analgesics) is unclear [11]. There is
evidence that active physiotherapy increases the propor-
tion of sciatica patients showing improvement and is espe-
cially effective for those with severe symptoms [13, 14].
The reviews reach conflicting conclusions about the role
of spinal injections, although these appear to provide pain
relief in the short-term [15, 16]. Surgery provides more
rapid recovery from the symptoms of sciatica although
outcomes are similar to those from non-surgical care, one
or two years later [4, 17]. Surgery and spinal injections are
associated with more frequent and more severe adverse
events [10], optimal selection criteria for eligible patients
for surgery (discectomy) are lacking [18], and immediate
referral to surgery for all sciatica patients is not a cost-
effective model of care [10].
In practical terms, current treatments range from pro-
viding information and advice, medications, exercise, trac-
tion, acupuncture and manual therapy, to more invasive
treatments such as spinal injections and surgery. Although
there is variation between clinicians, generally the current
model of care followed for sciatica is ‘stepped’. This typic-
ally means that initially there is a ‘wait and see’ period in
primary care with advice and pain medication, then for
those patients not improving after a period of weeks or
months, referral to a clinician such as a physiotherapist
might be considered, for treatments including exercise
and manual therapy. Subsequently, patients failing to
improve might be referred to specialist spinal services for
investigations and further management [2]. Currently the
only patients who are fast-tracked from primary care to
spinal specialist opinion are those with suspected cauda
equina syndrome or profound, widespread or progressive
neurological deficit, and those who need hospitalisation
due to pain severity. There are no robust estimates for the
proportion of patients consulting in UK primary care with
sciatica who proceed to spinal injection or spinal surgery,
although some old reports estimate that between 5-15% of
patients with sciatica proceed to disc surgery [18, 19].
Approximately 13% of patients consulting with sciatica in
UK primary care are referred to spinal specialist services
at some point following their initial primary care consult-
ation [20]. Currently, there is no evidence that can ro-
bustly guide decision making about which sciatica patients
to refer early for consideration of interventions such as
spinal injections and/or surgery.
The UK Spinal Taskforce [21] highlighted problems in
the management of sciatica and emphasised the urgent
need for good quality trial evidence to underpin treat-
ment decision-making, including better information
about the clinical and cost effectiveness of early referral
of patients with severe symptoms, for consideration of
secondary care treatments such as surgery or spinal
injections. A model of care is needed that does not over-
treat those with a good prognosis, yet promptly identi-
fies the patients who do need more active treatment to
help with symptoms and return to everyday function
including work [22].
A model of stratified care that uses information on the
risk of persistent disabling non-specific LBP (prognostic
risk: low, medium, high) and targets treatment accord-
ingly, has been shown to be superior to non-stratified pri-
mary care [23, 24]. The approach uses a brief self-report
tool - the STarT Back tool [25] which was developed for,
and validated with, primary care patients with non-
specific LBP (with and without leg pain). A similar model
of stratified care may be beneficial for sciatica patients
consulting in primary care, but evidence is lacking.
Trial aims and objectives
The overall aim is to investigate whether the manage-
ment of adult patients with sciatica presenting in pri-
mary care can be improved through a model of stratified
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care. The primary objective is to compare the clinical
effectiveness of stratified care to non-stratified care, in
terms of patient-reported time to resolution of sciatica
symptoms.
Secondary objectives are to: a) compare the clinical
effectiveness of stratified care to non-stratified care, on a
range of important outcomes, including physical function,
pain, quality of life, work loss, healthcare use and satisfac-
tion with treatment, b) compare the cost-effectiveness of
stratified care compared to non-stratified care, c)
investigate the impact of stratified care on service deliv-
ery, specifically the proportion of patients receiving
stratification-appropriate referrals and treatments, and d)
determine the acceptability of aspects of the stratified care
model, to patients and clinicians.
Methods
Design
The SCOPiC trial is a multicentre, pragmatic, assessor-
blind, two-arm randomised controlled trial (RCT), com-
paring stratified care versus non-stratified care for adults
with sciatica, with internal pilot and concurrent health
economic evaluation and linked qualitative study.
Setting
Participants will be recruited from approximately 30 gen-
eral practices in Staffordshire, North Shropshire, Cheshire,
and Wales, UK. The population in these localities is a mix
of urban, inner city, semi-rural and rural. The trial in-
volves National Health Service (NHS) general practices,
NHS physiotherapy services and NHS spinal specialist
services. A number of research clinics (SCOPiC sciatica
clinics), in which patients are screened for eligibility and
recruited to the trial, are based in primary care centres,
in Staffordshire, North Shropshire (patients from gen-
eral practices in Wales are seen in North Shropshire),
and Cheshire.
Participants
Participants are eligible for inclusion if they are aged 18
years and over, consulting at their general practice with
back and/or leg symptoms of any duration or severity
and their general practitioner (GP) (or other healthcare
practitioner (HCP) in the practice) suspects sciatica, are
able to communicate in English, willing to participate,
able to give full written consent, have access to a mobile
phone or landline, and following clinical assessment in
the SCOPiC research clinic have the diagnosis of sciatica
confirmed.
Exclusion criteria are: potentially serious spinal pathology
(such as cauda equina syndrome, malignancy, inflamma-
tory spondyloarthopathy), previous lumbar surgery, preg-
nancy, serious physical or mental co-morbidity preventing
them from attending the research clinic and/or undergoing
assessment and interventions, currently receiving ongoing
care from, or have been in consultation with, a secondary
care doctor or physiotherapist for the same problem in
the last 3 months, are currently participating in any
other sciatica research study.
Stratified care model for sciatica
Stratification algorithm
We devised an algorithm to identify those sciatica pa-
tients likely to need a fast-track referral from primary
care to specialist spinal services, and those who are likely
to do well with treatments available in primary care.
This algorithm was based on data analysis from the
ATLAS study cohort [20] which provided information
on the characteristics of sciatica patients most likely to
be referred to spinal specialist services. Full details of
the development of the stratification algorithm will be
provided in a separate paper. Here we give very brief
details on the stratification algorithm and the three
derived subgroups. We utilised prognostic information,
using the STarT Back tool [25], and clinical information
based on the following clinical examination findings:
interference with ability to work (including work around
the house), pain below the knee, intense leg pain, and
sensory changes in the painful leg during neurological
examination (loss of or reduced pin prick sensation in a
dermatomal distribution in the painful leg). The algo-
rithm allocates patients to one of three subgroups, and
each subgroup is matched with a care pathway. We allo-
cated patients to subgroup 1, which involves referral to
primary care for management options of low treatment
intensity, if their total score on the STarT Back tool was
less than or equal to 3 out of a possible 9. We used a
combination of the STarT Back tool score and a number
of findings from the clinical examination described
above to direct referral to primary care management
options of higher treatment intensity (subgroup 2), or
to fast-track patients to a specialist spinal opinion and
imaging tests (subgroup 3). The details of the care path-
ways for each of the three subgroups, are presented in
full later in the text, under the section ‘Stratified care
arm: Matched care pathways and their delivery’.
Recruitment procedures
Identification and invitation of potentially eligible patients
Participants are identified when they consult their GP (or
other healthcare practitioner (HCP) within the practice)
with symptoms of sciatica. When a patient with back and/
or leg pain consults, and an appropriate Read code [26] is
entered on the computer system, a ‘pop-up’ prompt
screen asks the GP if he/she thinks the patient might have
sciatica, and if so, to consider whether the patient is suit-
able to be invited to the SCOPiC sciatica clinic, taking into
account trial inclusion/exclusion criteria. Entering ‘yes’
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(that the patient has possible sciatica and is suitable to be
invited to the SCOPiC sciatica clinic) on the computer
system flags those patients thought to be suitable for invi-
tation to the clinic and allows the GP to briefly inform the
patient about the clinic and the trial. Using the same ‘pop
up’ screen the GP also is asked to record what their man-
agement plan would have been for the patient outside the
trial (‘continue with GP care’, ‘physiotherapy referral’, ‘spe-
cialist spinal referral’). This information will be sum-
marised at the end of the trial in order to describe GP
management preferences at first consultation (e.g. con-
tinue with GP care, refer to physiotherapy services or refer
to spinal specialist services).
On a weekly basis, letters inviting patients to the
SCOPiC sciatica clinic are mailed to all potentially eligible
patients identified from their consultation. The letter and
clinic information sheet explains that there is a research
study being hosted at the SCOPiC sciatica clinic. Patients
are invited to telephone the clinic administrator to make
an appointment at the SCOPiC sciatica clinic. During that
telephone call, the administrator carries out a brief check
for suitability for the clinic. Patients who are receiving or
have received care from alternative or complementary
HCP practitioners such as osteopaths, chiropractors, acu-
puncturists or others, are not be excluded but are advised,
where possible, to keep co-interventions to a minimum
during the treatment phase of the trial. The administrator
offers a clinic appointment within 10 working days. A
letter is sent to patients to confirm their appointment
details, together with a participant information sheet and
a baseline questionnaire. Approximately two days before
the clinic appointment, a clinic administrator telephones
patients to remind them about their appointment and ask
those who are interested in taking part in the research to
bring their completed questionnaire.
Weekly retrospective GP practice consultation records
review may also be used, if needed, as a second method
of identifying potentially eligible participants. With this
method there is a search for patients for whom the GP
has entered one of the agreed Read codes indicating he/
she suspects sciatica, so that if GPs overlook or do not
have time to complete the electronic ‘pop up’ screen in
the consultation, this method will ensure these patients
are identified retrospectively and also invited using the
same procedures described above. Duplication checks
will ensure that the same patient is not invited twice.
Full eligibility screening and informed consent
The SCOPiC sciatica clinics operate as integrated re-
search/service clinics. Physiotherapists will explain the
purpose of the clinic, and answer any questions patients
have about the clinic or the trial. Patients expressing inter-
est in participating in the trial proceed to have a standar-
dised assessment for sciatica by the physiotherapist, to
establish full eligibility and ascertain subgroup allocation.
Eligibility for the trial is based on the assessing physiother-
apist being ≥70% confident of a diagnosis of sciatica [27].
Patients who have leg pain thought by the assessing
physiotherapist to be due to causes other than sciatica are
excluded (for example: referred leg pain, hip pathology,
peripheral neuropathy, vascular pain), as are patients for
whom there is substantial diagnostic uncertainty. Patients
included in the trial will have pain in one or both legs,
plus at least one of the following self-reported symptoms
or clinical findings; leg pain approximating a dermatomal
distribution, leg pain worse or as bad as the back pain, leg
pain made worse by coughing/sneezing/straining, subject-
ive sensory symptoms approximating a dermatomal distri-
bution, any degree of objective neurological findings
relating to spinal nerve root (s) involvement such as sen-
sory or reflex changes or myotomal weakness, or positive
neural tension tests (straight leg raise (SLR), femoral nerve
stretch). The above symptoms and signs are part of the
presentation of sciatica [28, 29].
For patients who are eligible and interested in taking
part in the trial, the physiotherapist explains the trial in
detail, answer any questions and, if they are willing to
participate, takes written informed consent. Patients
who are ineligible or who do not wish to participate will
receive advice and education from the physiotherapist in
clinic and then continue with care as appropriate, out-
side the trial. Figure 1 outlines the SCOPiC recruitment
procedures.
Randomisation and allocation concealment
Eligible patients who consent to take part are rando-
mised to one of the two trial arms using a 1:1 web-
based randomisation service through Keele Clinical
Trials Unit (CTU), ensuring allocation concealment.
The clinic administrator uses the web-based random-
isation method (with a back-up process to telephone
the CTU for randomisation in the event of web access
failure), providing details of the centre (Staffordshire,
North Shropshire/Wales, Cheshire) and patient sub-
group allocation. Individual patients are randomised,
stratified by centre and subgroup allocation, using
random permuted blocks of varying size, to either
stratified care or non-stratified care. The administrator
informs the physiotherapist of the patient’s allocation
(stratified care arm or control arm) and delivery of
treatment will commence within the same SCOPiC
clinic visit. The patient’s GP is informed in writing that
the patient is participating in the trial but are not
informed about which arm of the trial the patient has
been randomised to. Usual clinician to clinician corres-
pondence continues as per normal practice and the
research does not interfere with this.
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Blinding and protection against bias
Selection bias at recruitment is avoided by separating
the processes of determining patient eligibility and treat-
ment allocation and by using random permuted blocks
overseen by the CTU, not allowing physiotherapists
assessing and treating patients to predict the next alloca-
tion in the clinic. Patients are told that the trial is com-
paring two primary care approaches for the treatment of
sciatica, one based on matching patients to treatment
using a simple tool which helps to decide on the treat-
ment pathway most likely to help them, and one based
on treatment needed as agreed by the physiotherapist in
clinic and themselves. Patients randomised to non-strati-
fied care are seen by physiotherapists who have not car-
ried out their detailed clinical assessment and eligibility
screen for the trial, and thus the treating physiotherapist
in the control arm will remain blind both to the details
of the stratification algorithm and the individual patient’s
subgroup status, in order to make sure that there is no
contamination between the two trial arms. It is not
possible to blind physiotherapists treating participants
randomised to the stratified care treatment arm, there-
fore, in order to further protect against contamination,
no physiotherapists treating patients in the stratified care
arm are involved in the treatment of any patients rando-
mised to the control arm. Research nurses blinded to
treatment allocation conduct primary outcome data
collection over the telephone (for participants not using
the automated text messages) and minimum data collec-
tion (secondary outcomes) over the telephone at 4 and
12-months follow-up, for patients who do not respond
to questionnaires. The risk of contamination from GPs
knowing to which arm a patient is randomised is very
low. However, we will check whether involvement in the
trial changes GPs’ referral habits for this condition by in-
creasing GPs’ awareness about sciatica. We will check
this by describing the proportion of sciatica patients
referred to other services from participating general
practices for the period of 12 months prior to the start
of the trial and for the duration of the trial recruitment
Fig. 1 Summary flow diagram of participant recruitment in the SCOPiC trial
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period. Using anonymised GP electronic records, we will
retrospectively check referral patterns as described
above. In qualitative interviews with the GPs we will also
collect data on whether involvement in the trial contrib-
uted to changes in GPs’ referral decisions for patients
with sciatica. The trial databases are password protected
to ensure that the research nurses and trial statisticians
remain blind to treatment allocation. Anonymised data
comparisons between consenting and non-consenting
individuals, dropouts and completers will be carried out
to evaluate external validity and risk of attrition bias.
Additionally, using validated outcome measures with
established reliability will reduce measurement error.
Audit of interventions
Treatment delivered in the intervention arm of the SCO-
PiC trial is recorded in a standardised format on Case
Report Forms (CRFs). This includes, date of start and
completion of treatment, number of treatments received
and types of interventions (i.e. exercise, advice, manual
therapy). Protocol deviations are reported and recorded.
Details of the care patients receive in the ‘fast-track’ path-
way and timeframe of any interventions delivered (such as
surgical or injection procedures) are collected by populat-
ing CRFs with the relevant information from the clinical
letters generated in the specialist clinics for each patient.
Following the 12-month follow-up, reviews of hospital
medical records for the patients in the ‘fast-track’ pathway
for information on the sciatica treatments they have
accessed will also be undertaken for completeness.
All physiotherapists who deliver care to patients in the
control arm of the SCOPiC trial also record treatment
details on a CRF. Similarly, this includes the dates of the
start and completion of treatment, number of treatments
and types of interventions received. Physiotherapy record
reviews are conducted in the cases of missing or incom-
plete CRFs for both stratified care and control participants.
Internal pilot
The internal pilot phase of the SCOPiC trial will assess
recruitment and follow-up rates over the first 8 months
of recruitment, success of GP practice recruitment and
retention, success of physiotherapy site recruitment
including training and engagement, adherence to the
treatment protocols, suitability of the patient selection
criteria, proportion of participants allocated to each of
the three subgroups according to the stratification algo-
rithm, time to magnetic resonance imaging scan (MRI)
and specialist opinion for those in the fast-track pathway
(subgroup 3), the event rate of the primary outcome,
and rate of missing data for the primary outcome up to
4-month follow-up for all participants recruited within
the 8 months of the pilot trial phase. Details of the
internal pilot analysis are described under the ‘Statistical
analyses’ section.
Stratified care arm: Matched care pathways and
the delivery of treatments
Physiotherapy management in primary care
Subgroup 1 (STarT Back tool; Low risk)
Patients in this subgroup are expected to have a good
prognosis and will receive a brief treatment package deliv-
ered by trial physiotherapists. In contrast to patients with
non-specific LBP and a score of 3 or less on the STarT
Back tool, patients with sciatica tend to have more severe
symptoms, hence the decision to offer a referral to phy-
siotherapy for brief treatment. Patients receive up to two
30-min sessions with the physiotherapist, with a target of
delivery over 4 weeks, in order to permit review where
needed but no further sessions will be offered. The pack-
age of care is tailored to the individual patient’s presenta-
tion and specific needs in order to support self-
management and reduce disability. It includes advice,
information, appropriate reassurance and education about
sciatica. It focuses on the expected good prognosis and re-
covery without the need for further tests or investigations,
the maintenance of activity levels including return to work
where appropriate, and lifestyle advice such as general ac-
tivity and weight control as appropriate as well as guid-
ance on self-management and management of future
flare-ups of sciatica. Pain relief and appropriate medica-
tion are also discussed with any suggested changes in anal-
gesia communicated to the patient and their GP for
consideration. To reinforce key messages, a sciatica book-
let (developed from existing educational materials already
available in the sciatica literature) will be given to the
patient along with an information sheet of local contacts
for exercise venues such as swimming pools, exercise
classes and physical activity opportunities.
Subgroup 2
Patients allocated to this subgroup receive a course of
physiotherapy treatment, tailored to their individual
needs. This matched treatment package is delivered in
an initial 45-min session with a target of up to 6 further
30-min sessions over 6 to 12 weeks. The STarT Back
tool score and clinical assessment findings guide the
treating physiotherapist in targeting management to-
wards the physical and psychosocial factors that are par-
ticular problems for each patient. The physiotherapist
agrees an individualised treatment plan with the patient
according to their need and best current evidence. The
main aims of treatment are to reduce pain, decrease
disability and address modifiable physical and psycho-
logical obstacles to recovery. Management plans include
some or all of the following: advice, explanation, reassur-
ance and education, medication review and advice (with
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any suggestions on analgesia communicated to the patient
and their GP for consideration), exercise (McKenzie ‘direc-
tional preference exercises’, strengthening-muscle stability
exercises, general fitness and mobility exercises and guid-
ance on pacing using graded activity principles depending
on patient presentation), manual therapy techniques (joint
and/or soft tissue), acupuncture and advice about and plans
for return to normal activities and work as appropriate.
Psychological obstacles to recovery, such as fear-avoidance
beliefs, pain related low mood and distress or anxiety,
unhelpful or erroneous beliefs about back pain and sciatica
and catastrophising are also addressed as part of the
physiotherapy treatment. The same sciatica booklet and
information sheet of local contacts for exercise venues, as
those given to patients in subgroup 1, are also given to
patients in subgroup 2. Management of future flare-ups of
sciatica are addressed as part of the treatment plan.
Consistent with evidence based guidelines, bed rest, trac-
tion, massage and electrotherapy are not included in the
treatment options [10].
The treatments for subgroups 1 and 2, are delivered in
primary care by NHS physiotherapists. Participants con-
tinue to be able to access other care via their GP. The
physiotherapists treating patients in subgroups 1 and 2
are responsible for providing good clinical governance to
their patients and will be permitted to overrule the
stratification algorithm recommendation for matched
care pathways, if they strongly believe this is necessary.
As in our previous trials23, such protocol deviations are
expected to be rare and will always be discussed with
the treating physiotherapist’s spinal specialist mentor
and the trial principal investigator (PI), and documented.
Fast-track care pathway to specialist spinal service
Subgroup 3
Patients allocated to subgroup 3 are fast-tracked to spe-
cialist assessment and opinion about suitability for other
treatments, such as spinal injections or surgery. ‘Fast-
track’ is defined as immediate referral from the SCOPiC
sciatica clinic to specialist spinal assessment with service
level agreements in place with participating NHS ser-
vices to ensure that assessment will take place within 4
weeks of the patient’s SCOPiC sciatica clinic appoint-
ment. An MRI scan is part of the specialist spinal assess-
ment for the patients in the ‘fast-track’ care pathway. A
report on the MRI scan will be provided by a consultant
radiologist, as per normal NHS clinical practice. The
spinal specialist has access to the MRI results, as part of
their assessment of patients in this ‘fast-track’ pathway.
It is important to note that the ‘fast-track’ pathway is to
specialist assessment and opinion and not to surgery or
injection. Patients with contraindications to MRI see the
spinal specialist who will decide on alternative imaging
tests as necessary. The specialist, in discussion with the
patient, determines the most appropriate treatment
based on assessment and MRI findings and patient
preference.
These spinal specialist services within the participating
NHS services, include specialist clinics at the primary/
secondary care interface (usually delivered by extended
scope spinal physiotherapy specialists), spinal ortho-
paedic and pain clinic teams. The first appointment with
specialists for patients allocated to the ‘fast-track’ path-
way is at the primary / secondary care interface. These
NHS services are delivered by specialist spinal physio-
therapists (extended scope practitioners), any referrals to
other spinal specialist services (orthopaedics, neurosur-
gery or pain clinic) are decided as part of routine care at
this point.
Non-stratified care and its delivery
The control arm of the SCOPiC trial is based on non-
stratified primary care, delivered by physiotherapists. Pa-
tients randomised to the control arm are treated by a
physiotherapist in the SCOPiC sciatica clinic. For these
patients, treatment includes a one-off session (in the
same clinic visit) of advice and education. The treating
physiotherapist then decides whether the patient should
be discharged back to the care of their GP or be referred
for community physiotherapy or to specialist spinal ser-
vices. If an onward referral is required this is arranged
by the physiotherapist at the clinic.
As previously mentioned, in order to avoid contamin-
ation between the stratified care arm and control arm, at
the SCOPiC clinic, different physiotherapists provide treat-
ment for patients in each of the two trial arms and the
physiotherapists who are providing treatment to control
care patients are unaware of the details of the stratification
algorithm and individual participants’ group status.
Training for participating physiotherapists
Participating physiotherapists will attend training work-
shops with the trial team prior to the start of patient re-
cruitment and treatment. Those delivering the one-off
treatment for patients in the control arm in the SCOPiC
clinic, will take part in a half-day workshop about trial
procedures, importance of avoiding contamination be-
tween trial arms and the completion of trial CRFs.
Those involved in the stratified care arm of the trial
will attend three days of training. The focus of the train-
ing will be on carrying out the standardised assessment
according to agreed protocols to identify patients with
sciatica for participation in the trial, the stratification
algorithm, taking informed consent, the delivery of
evidence based physiotherapy interventions in line with
the biopsychosocial model of care and the procedures of
the trial, avoiding contamination between trial arms, and
the completion of trial CRFs.
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The training will be supplemented by comprehensive
written material on the trial procedures, and on guide-
lines and treatment algorithms for the evidence based
assessment and treatment of patients with sciatica. To
maximise protocol fidelity, physiotherapists treating
patients in subgroups 1 and 2, will have support as
required, this will be provided by the research team’s
spinal physiotherapy specialists from the spinal services
participating in the trial.
Outcome measures and data collection
Primary outcome
The primary outcome measure is time to first resolution
of symptoms of sciatica, measured on a 6-point ordered
categorical scale: ‘completely recovered’, ‘much better’,
‘better’, ‘same/ no change’, ‘worse’ and ‘much worse’ – the
anchor being against the patients’ baseline symptoms
when they attended the SCOPiC sciatica clinic (“com-
pared to how you were at the SCOPiC clinic X weeks/
months ago, how are your back and leg symptoms
today?”). Patient-reported resolution of symptoms is de-
fined as a response of either ‘completely recovered’ or
‘much better’, collected using regular text messages (or
brief phone calls where text messaging is not possible).
Data collection for the primary outcome occurs weekly,
starting on the first Sunday following the participant’s as-
sessment at the SCOPiC sciatica clinic, for the first 4
months for all participants. Then between 4 and 12-
month follow-up, the text message data collection changes
to once every 4 weeks, or until ‘stable resolution’ of symp-
toms, which is defined as 2 consecutive months’ responses
of ‘completely recovered’ or ‘much better’. After stable
resolution, data collection for the primary outcome via
text message ceases. 94% of UK adults have a mobile
phone (https://www.ofcom.org.uk./facts) and previous re-
search has shown that weekly text messages are a useful
method of data collection to examine the clinical course
of back pain in primary care, with high mean response
rate of 83% [30]. Participants who do not respond to their
first week’s text message receive a reminder message 48 h
later, and those who still do not respond are mailed a post-
card the next day. Participants who do not respond to the
second week’s text message receive a reminder message
48 h later, and those who still do not respond receive a
phone call from a research nurse after at least a further 24
h. For subsequent non-response the reminder processes
described is repeated. If the participant continues not to
provide a response using text message there is an option
to transfer to data collection by brief phone call.
Secondary outcomes
Secondary clinical outcomes evaluate health status at 4
and 12 months using participant self-completed postal
questionnaires with postal reminders and minimum data
collection over the telephone, by research nurses. A text
message is sent to participants at 4 and 12-month
follow-up to notify them that the SCOPiC follow-up
questionnaire will soon arrive in the post. Measures in-
clude Global Perceived Change ((GPC) (6-point Likert
scale as per the primary outcome data collection)), phys-
ical function limitations (sciatica version of the Roland
and Morris Disability Questionnaire) [31], overall impact
of sciatica symptoms (Sciatica Bothersomeness Index)
[32], pain intensity of back and leg pain [33], sleep disturb-
ance (Jenkins sleep questionnaire) [34], fear of movement
(Tampa Scale of Kinesiophobia) [35], anxiety and depres-
sion (Hospital Anxiety and Depression Scale) [36], risk of
poor outcome according to the STarT Back tool [25], health
related quality of life (EQ-5D-5L) [37], general health (SF-
1) [38], neuropathic pain using the S-LANSS (self-report
Leeds Assessment of Neuropathic Symptoms and
Signs) [39], days lost from work and productivity loss
due to sciatica, pain medication, adverse events and sat-
isfaction with care received and its results. See Table 1
presents an overview of procedures and measures used
according to the SPIRIT statement (Chan et al. [40]).
Process outcomes
Process outcomes are collected to investigate the impact
of stratified care on service delivery. Numbers and pro-
portions of patients in each arm of the trial receiving ap-
propriate referrals and treatments according to their
subgroup allocation, and the timing of starting treat-
ment, are collected from CRFs, patient questionnaires
and record reviews from participating NHS services.
Health economic outcomes
Health economic outcomes are collected to determine the
costs of the interventions (stratified care and control) and
other sciatica-specific healthcare utilisation. Resource use
information is obtained on primary care consultations
(GPs and other HCPs in the practice), secondary care con-
sultations (e.g. hospital consultants), prescriptions, hospital
based procedures (diagnostic tests, injections), nature and
length of inpatient stays, surgery and over-the-counter pur-
chases by patients. Patients are asked to distinguish be-
tween UK NHS and private provision. Cost data are
collected via participant questionnaires at 4 and 12
months. If hospital records data on sciatica-related surgery
or injections (to supplement patient-reported data) can be
obtained, this data will be included in a sensitivity analysis.
Unit costs are obtained from standard sources including
the British National Formulary (BNF) [41], Unit Costs of
Health and Social Care [42] and NHS Reference costs. In-
formation is also collected from participants about
their occupational status, sciatica-related time off
work and reduced work performance (presenteeism)
[43], to enable the calculation of productivity costs,
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Table 1 Overview of enrolment, interventions, and assessments
*The interventions and their delivery are described in detail in the manuscript. Treatments are tailored to the individual participant and likely to have different
frequency and duration for each participant. Overall, treatment for most participant is expected to be completed within 4 months from randomization
a The trial’s primary outcome is time to symptoms resolution. Data collection with text messages for the primary outcome occurs weekly for the first 4 months for all
participants. Between 4 and 12-month follow-up, the text message data collection changes to once every 4 weeks, or until ‘stable resolution’ of symptoms, which is defined
as 2 consecutive months’ responses of ‘completely recovered’ or ‘much better’. After stable resolution, data collection for the primary outcome via text message ceases
b At 4 and 12 months follow-up, data collection is via postal questionnaires
c Participants and clinicians are asked to report any adverse and/or serious adverse events. Patients are asked about adverse events in the follow-up questionnaires
d Global perceived change is collected via text messages or telephone calls, and in the follow-up questionnaires at 4 and 12 months
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allowing analysis from a societal cost perspective.
The average wage for each respondent will be identi-
fied using UK Standard Occupational Classification
coding [44] and annual earnings data for each job
type [45]. The analysis will use the human capital
approach, and the self-reported days of absence will
be multiplied by the respondent-specific wage rate.
The outcome of interest for the economic analysis is
quality-adjusted life years (QALYs) and these will be
calculated using EQ-5D-5L responses obtained at
baseline, 4 and 12 months.
Adverse events
Information is collected on adverse events (AEs) ex-
perienced by trial participants and potentially related
to trial interventions or procedures. Physiotherapists
treating patients in the SCOPiC trial are asked to
report potential AEs by the use of CRFs or report to
the trial team. Patients are asked about AEs in the
follow-up questionnaires. Expected AEs include for
example a transient increase in pain as a result of a
new exercise programme. Any serious adverse events
(SAEs), defined as an event that is life threatening,
results in death, unscheduled hospitalisation, or sig-
nificant disability, is immediately reported to the trial
team according to the procedures described in the
Keele CTU standard operating procedures for SAEs.
Any SAEs considered to be related to the trial proce-
dures or interventions will be reported to the main
Research Ethics Committee by the Chief Investigator
within 15 days of becoming aware of the event. In
addition, all such events will be reported to the trial
sponsor, Trial Steering Committee (TSC) and Data
Monitoring Committee (DMC).
Qualitative study
The aim of the linked qualitative study is to understand
the acceptability of the ‘fast-track’ pathway in the strati-
fied care arm of the trial, to patients and clinicians.
Qualitative research on patients’ experiences of sciatica
and its management is scarce [46, 47], especially in those
with most severe symptoms, and qualitative studies that
report clinicians’ views of managing this condition are
even less common [48]. In the SCOPiC trial stratified
care arm the ‘fast-track’ pathway to spinal specialist as-
sessment and opinion is novel, and the focus of the
qualitative study is on patients in this subgroup and the
clinicians involved in their management.
A purposive sample of patients randomised to the
stratified care arm and who are on the ‘fast-track’ path-
way will be invited for interview based on treatment
centre and patient demographics including age, gender,
baseline leg pain severity/disability, and also response to
treatment. Interviews will be conducted after the 4
month follow-up point.
Potential interviewees will be sent an invitation letter
with an information leaflet about the interview, follow-
ing which a researcher will contact them by phone, and
arrangements made with those who agree to participate.
Consent will be obtained at the start of the interview, ei-
ther in writing if the interview is face-to-face, or audio-
recorded if the interview is over the telephone. A semi-
structured topic guide will be developed, exploring pa-
tients’ views of their clinical care, its appropriateness
and timeliness for addressing their problem, and the
time taken to assessment, treatment (s) and symptom
resolution. Patients’ experience of sciatica symptoms and
their impact will also be explored to provide context in
terms of treatments received. Participating spinal spe-
cialist clinicians (spinal physiotherapy specialists, spinal
surgeons), and a sample of participating GPs will be in-
vited for interview after the trial finishes participant re-
cruitment. Again, using a semi-structured topic guide,
the interviews will explore clinicians’ views about the ac-
ceptability of the ‘fast-track’ pathway, the suitability of
patients on this pathway, and explore how the ‘fast-track’
pathway compares with usual care, what the added value
of the ‘fast-track’ pathway might be for this subgroup of
sciatica patients, and what, if any, limitations there
might be. In interviews with GPs we will also explore
their perceptions of whether their involvement in the
trial contributed to changes in their referral decisions
for patients with sciatica. The same invitation and con-
sent process as described above for patients will be
followed with the clinicians. We estimate that sufficient
data saturation [49] will be reached with a sample of 20
to 25 patients’ and clinicians’ interviews (total of approx.
40 to 50 interviews).
Statistical analyses
The trial analysis will be conducted and reported follow-




The primary analysis will compare time to self-reported
resolution between stratified care and non-stratified
care, on an intention-to-treat basis. A Kaplan-Meier sur-
vival analysis will estimate the time from randomisation
until first resolution of symptoms. Participants who drop
out of the trial through active withdrawal will be cen-
sored at the time this occurs (by contrast, participants
not responding at any time point will continue to be
followed-up until they actively withdraw). This will pro-
vide the data for comparing the relative mean and me-
dian survival times of the two trial arms. A Cox
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proportional hazards regression analysis will compare
time to resolution between arms by calculation of a
hazard ratio (HR) of rates of resolution adjusted for
centre, patient stratification group (subgroups: 1, 2, 3)
and baseline pain duration. The HR will be presented
along with a 95% confidence interval for the HR; a p-
value < 0.05 (two-tailed) based on the Wald test statis-
tic will signify rejection of the null hypothesis of no
difference in recovery time between the two arms. A
statistically significant p-value with HR > 1 would in-
dicate statistically significant shorter time to recovery
for stratified care compared to control; a statistically
significant p-value with HR < 1 would indicate a (stat-
istical) significantly longer time to recovery for strati-
fied care compared to control. The analysis will
account for physiotherapist effect (proportional Cox
hazards frailty model).
Sensitivity analyses (of the primary endpoint)
The following sensitivity analyses will be carried out to
test the rigour and robustness of the primary outcome
evaluation through evaluation of:
 alternative assumptions regarding missing data – for
the primary evaluation, missing data are assumed to
be synonymous with non-recovery. The primary
evaluation is based on ‘recovery’ at the first point of
a positive response, but if any missing data immedi-
ately precede this response then all these observa-
tions are assumed to be indicative of ‘non-recovery’
– an additional sensitivity analysis will set the time
interval of recovery as the mean time between the
participant’s last response (indicating ‘non-reso-
lution’) and the time at which ‘resolution’ is first
classified. A more extreme sensitivity analysis will
take the contrary view on missingness to equate to,
and imputed as, a ‘resolved’ case.
 alternative assumption regarding interval censoring
– to account for the fact that only the interval of
time within which the resolution occurred is known,
and not the exact time (especially after the first 16
weeks when outcome data is collected monthly). A
further sensitivity analysis will use methods that
allow for interval censoring.
 secondary definitions of good outcome - we will use
three separate secondary classifications based on
‘stable resolution’, defined as: two consecutive
recordings of ‘completely recovered’ or ‘much
better’; ‘improvement’, defined as: completely
recovered’, ‘much better’ or ‘better’, through single
response, and ‘stable improvement’, defined as:
‘completely recovered’, ‘much better’ or ‘better’,
through two consecutive responses.
 analysis of participants in the stratified care arm
that: (i) have complete follow-up – i.e. not including
censoring, and (ii) receive the treatment pathway
that is correctly matched to their subgroup – as per
treatment protocol.
Exploratory subgroup analyses
A small number of re-analyses of the primary endpoint
analysis of time to resolution will be carried out to in-
clude testing the effectiveness of stratified care for those
with/without suspected disc-related radicular pain as de-
termined by clinical assessment, and for patients in each
of the stratification subgroups (subgroups 1, 2 and 3).
Descriptive statistical summaries will be provided
through mean/median time to resolution per treatment
arm and per patient subgroup (subgroups 1, 2, 3) ac-
cording to suspected/not suspected disc-related radicu-
lar pain. Tests of statistical significance will be through
evaluation of 95% interval estimates / p-values for the
interaction term for the product of group variable (with/
without suspected disc-related radicular pain) by treat-
ment arm within the Cox regression model adjusting for
centre, stratification group (stratifying variables), and
pain duration.
Secondary outcomes analysis
The analysis will provide between-arm differences in sec-
ondary outcomes at 4 and 12 months and provide point
and 95% interval estimates from longitudinal linear and
logistic mixed effect regression models as appropriate to
the outcome data being analysed adjusting for centre,
stratification subgroup (1, 2, 3) (stratifying variables) and
baseline pain duration. Descriptive summary of mean
scores for the two trial arms and difference in mean scores
(numerical outcomes) and frequency counts (percentages)
along with odds ratios (categorical outcomes) will be
presented, with between-arm comparisons being pre-
sented in the form of point and 95% interval estimates,
alongside p-values for the test of statistical association.
Assumption checking
The Cox regression model assumption of proportional
hazards will be examined in two ways: (i) firstly, through
graphical review of the survival curves – if the survival
curves are observed to cross this would indicate non-
proportionality; (ii) through inclusion of a time-arm inter-
action in the regression model with statistical significance
of this term signifying important deviation from the as-
sumption of proportional hazards. If either of the two ex-
aminations shows violation of the proportional hazards
assumption then alternative statistical testing will be per-
formed using an unadjusted log rank test.
For the linear models we will examine inverse normal
plots to check for normality (in the event of any
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reasonable violation we will use a suitable data-
transformation function). Potential covariance structures
will be explored for goodness-of-fit of mixed models
through comparing likelihood and Bayesian Information
Criteria (BIC).
Process outcomes analysis
Descriptive statistics will be used to examine healthcare
resource utilisation by stratification subgroup (subgroups
1, 2, 3) and the number and percentage of participants
who proceeded to secondary care treatments, and the
types of interventions they received, in both trial arms –
and by stratification subgroup (1, 2, 3). Non-parametric
tests will be used to test for between-arm comparisons.
Internal pilot analysis
Analysis of the internal pilot data will provide information
on success of GP practice and physiotherapy site
recruitment and retention, recruitment and follow-up
rates (over the first 8 months of recruitment), adherence
to the treatment protocols, proportion of participants allo-
cated to each of the three subgroups (1, 2, 3), time to ‘fast-
track’ MRI and specialist opinion for those in subgroup 3
(‘fast-track’ pathway), the event rate of the primary out-
come (recovery) up to 4-month follow-up for all partici-
pants (stratified care and control arms) recruited within
the 8-month pilot phase in order to check the sample size
calculation assumptions. The rate of missing data for the
primary outcome will also be checked in the pilot phase
for all participants. No formal interim analysis of partici-
pants’ clinical outcomes is proposed for the internal pilot.
Sample size
We have calculated a sample size of 470 participants in
total, in order to test for superiority of stratified care
compared to non-stratified care. The primary outcome
of interest in the SCOPiC trial is time to resolution of
symptoms (defined as patient self-report of being ‘com-
pletely recovered’ or ‘much better’ compared to baseline
(from the 6-point ordinal GPC scale). In our previous
trial of stratified care for LBP [23], nearly 60% of pa-
tients in total had a clinically important improvement
on the GPC scale at 4 and/or 12-month follow up; the
absolute difference between arms of that trial at 4
months was 11%. If proportional hazards are to be as-
sumed (i.e. in this case assumed relative rate of ‘reso-
lution’), this difference would equate to an HR in the
interval 1.4 - 1.5. Allowing for 20% dropout, a sample
size of 470 (235 per treatment arm) is required to detect
an HR between 1.4 - 1.5 with 80-90% power (given a
two-tailed significance level of 5%), assuming a rate of
resolution in excess of 60%, and intra-class correlation
(ICC) for physiotherapist effect less than 0.01 (based on
estimates from other primary care trials [23, 53], and
allowing for a coefficient of variation in physiotherapist
cluster size of 0.65 [54]; specifically:
 an HR of 1.4 in median survival times with 90%
power (if all participants in the trial are recovered by
12-month follow-up and ICC for therapist effect is
<0.001) (least conservative)
 an HR of 1.5 in median survival times with 80%
power (if 60-65% of participants in the trial are re-
covered by 12-month follow-up and ICC for physio-
therapist effect is 0.01) (most conservative)
An HR above 1 (and correspondingly lower ‘survival’
function) in this context is a positive result in contrast
to traditional survival analysis of mortality.
This sample size will also provide more than 80%
power to detect a ‘small’ to ‘moderate’ standardised
mean difference (effect size) of 0.35 [55] between the
two trial arms in a key secondary outcome of physical
disability at 12-month follow-up, allowing for an ICC for
physiotherapist effect of 0.01.
Economic analysis
The within-trial health economic analysis will determine
the cost-effectiveness of stratified care compared with
non-stratified care. An incremental cost-utility analysis
will be undertaken using participants responses to the
EQ-5D-5L questionnaire to calculate the cost per QALY
gained. The base-case analysis will adopt a health care
perspective, incorporating UK NHS and private sciatica-
related healthcare resources utilised during the 12-
month follow-up period. Analysis from a wider societal
perspective will explore the impact on the results when
productivity costs are taken into account. Additional ex-
ploratory analyses will consider the cost-effectiveness of
stratified care compared with non-stratified care for par-
ticipants in each subgroup (subgroups 1, 2 and 3 separ-
ately), a strategy used previously in studies of stratified
care for LBP [56, 57]. Deterministic and probabilistic
sensitivity analyses will be conducted to test the robust-
ness of the results and overall uncertainty in the trial
cost and outcome data respectively. Cost-utility planes
and acceptability curves will be derived in order to pro-
vide a graphical display (plane and curve) and quantifi-
cation (curve) of the level of uncertainty around
incremental cost-effectiveness ratios (ICERs).
Qualitative analysis
Audio recordings of interviews will be transcribed verba-
tim, checked and anonymised. Data will be managed and
shared using NVivo software, fully coded and analysed
thematically [58]. To ensure sufficient data saturation,
analysis will follow an iterative process, with topic guides
being revised in light of emergent themes. There will be
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a clearly documented and on-going process of detailed
coding, both within and across cases searching for con-
firmatory and contradictory findings [59]. Data from the
patient interviews will also be compared for differences
and similarities with the outcome data from the trial
[60]. Emerging themes will be explored and discussed at
regular trial team meetings which will include clinicians
and social scientists. In addition, early findings from the
qualitative interviews will be presented to our research
user group, which includes individuals who have experi-
enced sciatica symptoms, and their views of the data in-
corporated into further data collection and analysis.
Trial organisation and monitoring
The trial is sponsored by Keele University. The day to
day operation of the trial will be overseen by the Trial
Management Group (TMG) and all trial procedures will
adhere to Keele CTU standard operating procedures.
The trial is monitored by an independent TSC with ex-
pertise in LBP, sciatica and clinical trials. An independ-
ent DMC is tasked with monitoring patient safety and
trial data integrity. During the trial period through to
12-month follow-up, no interim analyses are planned,
unless judged necessary by the DMC. The TSC, DMC,
TMG and clinicians involved will remain unaware of the
trial results until all data are cleaned, checked and ana-
lysed after the 12-month data are collected.
Data confidentiality and archiving
All trial-related information will be stored securely at
Keele CTU, Keele University. Data will be anonymised
using coded identification numbers and the data and the
linking code will be stored in separate locations, under
password protection. Access to the data will be to the
small number of individuals necessary for quality con-
trol, audit and analysis. We will publish and communi-
cate the trial results regardless of the outcome of the
trial. Data from the SCOPiC trial will be archived and
made available for future, secondary analysis and data
pooling purposes, by the SCOPiC team or other research
teams.
Ethics
The trial received ethical approval by the National Re-
search Ethics Service (NRES) Committee West Midlands
- Solihull (17/03/15): Project Reference Number: 15/
WM/0078. Site-specific approvals have been received
from the appropriate local R&D offices. The trial is be-
ing conducted in accordance with the ethical principles
in the Declaration of Helsinki and good practice guide-
lines on the proper conduct of research.
Patient and Public Involvement
We previously interviewed patients with sciatica and
they highlighted its impact, the need for clearer informa-
tion on treatment and prognosis and patients’ willing-
ness to balance their desire for pain relief with adverse
effects [46]. Whilst planning the SCOPiC trial we held a
workshop with three patient representatives (who cur-
rently had sciatica or had suffered with it in the past)
from a research user group. This highlighted the import-
ance of early assessment and diagnosis and the need to
get patients to treatments that match their problem
more quickly. They all felt that early pain relief is the
key outcome, given the severity of the pain and that
regular, brief, text messages or phone calls that collect
data about symptoms, were acceptable. Two patient rep-
resentatives are members of the TSC for the SCOPiC
trial. Members of a wider research user group advised
on the study documents, the language of the text messa-
ging and the interpretation of data from the qualitative
interviews with patients.
Discussion
This paper presents the rationale for, and the design and
processes of the SCOPiC trial. The trial is investigating
the clinical and cost-effectiveness of stratified care (sub-
grouping patients and matching them to one of three
care pathways) for patients consulting in primary care
with symptoms of sciatica. The novelty of this trial is
threefold. First is the use of information about a patient’s
risk of persistent physical disability due to the pain, and
findings from the clinical examination, in order to allo-
cate patients to one of three subgroups. Second is the
matched care pathways. Subgroups 1 and 2 are expected
to do well with conservative treatment in the form of
physiotherapy, with patients in subgroup 1 receiving up
to two brief physiotherapy sessions, and patients in sub-
group 2 receiving a course of up to six physiotherapy
sessions. Patients in subgroup 3 are those more likely to
need a referral to specialist services and are ‘fast-tracked’
to imaging tests and specialist spinal services for an
opinion on management. The third novel feature is the
choice of primary outcome, time to symptom resolution
assessed regularly using text messages.
The results of the SCOPiC trial will inform patients,
clinicians, service commissioners, and future clinical
guidelines, as to the clinical and cost-effectiveness of
stratified care for sciatica. We anticipate participant re-
cruitment will be completed in 2017, and 12-month
follow-up data collection will be completed in 2018.
Trial status
Recruitment is ongoing. Results are expected in 2018.
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